Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical Reviews in Allergy & Immunology
Published in: Clinical Reviews in Allergy & Immunology 3/2017

01-12-2017

Skin Manifestations of Inflammatory Bowel Disease

Authors: Thomas Greuter, Alexander Navarini, Stephan R. Vavricka

Published in: Clinical Reviews in Allergy & Immunology | Issue 3/2017

Login to get access

Abstract

Inflammatory bowel disease (IBD) with its two main subtypes Crohn’s disease and ulcerative colitis is not restricted to the gastrointestinal tract. Indeed, so-called extraintestinal manifestations (EIMs) are frequent and considerably affect morbidity and mortality. The prevalence of EIMs ranges from 6 to 47%. In up to one quarter of the patients, EIMs can present even before an IBD diagnosis is established. The pathophysiology of EIMs remains elusive, although data from clinical trials demonstrating anti-tumor necrosis factor (TNF) efficacy suggest a common pathogenic link between intestinal and extraintestinal disease activity. However, not all EIMs parallel intestinal disease. Skin lesions are usually classified based on their pathophysiological association with the underlying intestinal disease into four categories: (1) specific, (2) reactive, (3) associated, and (4) treatment-induced manifestations. Cutaneous manifestations include erythema nodosum (EN), pyoderma gangrenosum (PG), Sweet’s syndrome, and oral lesions, with EN being the most commonly reported and PG showing the most debilitating disease course. Anti-TNF-induced skin reactions are a new, but increasingly recognized phenomenon, which can be eventually misinterpreted as psoriatic lesions. Medical treatment modalities are limited with topical and systemic steroids being the most frequently employed agents. If EIMs parallel intestinal disease activity, the therapeutic cornerstone usually is the management of underlying intestinal disease activity rather than direct treatment of the EIMs. However, increasing evidence for anti-TNF agents’ efficacy in EIM management has changed the approach to complicating and debilitating disease courses. In the case of anti-TNF-induced lesions, topical steroids are usually sufficient and discontinuation of anti-TNF is seldom warranted. In this review, we summarize current knowledge on cutaneous EIMs, their diagnostic criteria and clinical presentation, natural history, pathogenesis, and treatment options.
Literature
1.
Shivashankar R, Tremaine WJ, Harmsen WS, Loftus EV (2016) Incidence and prevalence of Crohn’s disease and ulcerative colitis in Olmsted County, Minnesota from 1970 through 2010. Clin Gastroenterol Hepatol 15(6):857–863
2.
Loftus EV, Sandborn WJ (2002) Epidemiology of inflammatory bowel disease. Gastroenterol Clin N Am 31(1):1–20CrossRef
3.
4.
Bernstein CN, Blanchard JF, Rawsthorne P, Yu N (2001) The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. Am J Gastroenterol 96(4):1116–1122PubMedCrossRef
5.
Bernstein CN, Wajda A, Blanchard JF (2005) The clustering of other chronic inflammatory diseases in inflammatory bowel disease: a population-based study. Gastroenterology 129(3):827–836PubMedCrossRef
6.
Mendoza JL, Lana R, Taxonera C, Alba C, Izquierdo S, Díaz-Rubio M. Extraintestinal manifestations in inflammatory bowel disease: differences between Crohn’s disease and ulcerative colitis. Med Clin (Barc). 2005;125(8):297–300.
7.
Ricart E, Panaccione R, Loftus EV, Tremaine WJ, Harmsen WS, Zinsmeister AR et al (2004) Autoimmune disorders and extraintestinal manifestations in first-degree familial and sporadic inflammatory bowel disease: a case-control study. Inflamm Bowel Dis 10(3):207–214PubMedCrossRef
8.
Rankin GB, Watts HD, Melnyk CS, Kelley ML (1979) National Cooperative Crohn’s Disease Study: extraintestinal manifestations and perianal complications. Gastroenterology 77(4 Pt 2):914–920PubMed
9.
Su CG, Judge TA, Lichtenstein GR (2002) Extraintestinal manifestations of inflammatory bowel disease. Gastroenterol Clin N Am 31(1):307–327CrossRef
10.
Veloso FT, Carvalho J, Magro F (1996) Immune-related systemic manifestations of inflammatory bowel disease. A prospective study of 792 patients. J Clin Gastroenterol 23(1):29–34PubMedCrossRef
11.
Vavricka SR, Brun L, Ballabeni P, Pittet V, Prinz Vavricka BM, Zeitz J et al (2011) Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort. Am J Gastroenterol 106(1):110–119PubMedCrossRef
12.
Vavricka SR, Scharl M, Gubler M, Rogler G (2014) Biologics for extraintestinal manifestations of IBD. Curr Drug Targets 15(11):1064–1073PubMedCrossRef
13.
Tontini GE, Vecchi M, Pastorelli L, Neurath MF, Neumann H (2015) Differential diagnosis in inflammatory bowel disease colitis: state of the art and future perspectives. World J Gastroenterol 21(1):21–46PubMedPubMedCentralCrossRef
14.
15.
16.
17.
18.
Magro F, Gionchetti P, Eliakim R, Ardizzone S, Armuzzi A, Barreiro-de Acosta M, et al. (2017) Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders. J Crohns Colitis 11(6):649–670
19.
Gomollón F, Dignass A, Annese V, Tilg H, Van Assche G, Lindsay JO et al (2017) Third European evidence-based consensus on the diagnosis and management of Crohn’s disease 2016: part 1: diagnosis and medical management. J Crohns Colitis. 11(1):3–25PubMedCrossRef
20.
21.
Sands BE (2004) From symptom to diagnosis: clinical distinctions among various forms of intestinal inflammation. Gastroenterology 126(6):1518–1532PubMedCrossRef
22.
Charpentier C, Salleron J, Savoye G, Fumery M, Merle V, Laberenne JE et al (2014) Natural history of elderly-onset inflammatory bowel disease: a population-based cohort study. Gut 63(3):423–432PubMedCrossRef
23.
Lennard-Jones JE, Shivananda S (1997) Clinical uniformity of inflammatory bowel disease a presentation and during the first year of disease in the north and south of Europe. EC-IBD Study Group. Eur J Gastroenterol Hepatol 9(4):353–359PubMedCrossRef
24.
Hampe J, Cuthbert A, Croucher PJ, Mirza MM, Mascheretti S, Fisher S et al (2001) Association between insertion mutation in NOD2 gene and Crohn’s disease in German and British populations. Lancet 357(9272):1925–1928PubMedCrossRef
25.
Hugot JP, Chamaillard M, Zouali H, Lesage S, Cézard JP, Belaiche J et al (2001) Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn’s disease. Nature 411(6837):599–603PubMedCrossRef
26.
Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R et al (2001) A frameshift mutation in NOD2 associated with susceptibility to Crohn’s disease. Nature 411(6837):603–606PubMedCrossRef
27.
Stappenbeck TS, Rioux JD, Mizoguchi A, Saitoh T, Huett A, Darfeuille-Michaud A et al (2011) Crohn disease: a current perspective on genetics, autophagy and immunity. Autophagy 7(4):355–374PubMedPubMedCentralCrossRef
28.
Kostic AD, Xavier RJ, Gevers D (2014) The microbiome in inflammatory bowel disease: current status and the future ahead. Gastroenterology 146(6):1489–1499PubMedPubMedCentralCrossRef
29.
Norman JM, Handley SA, Baldridge MT, Droit L, Liu CY, Keller BC et al (2015) Disease-specific alterations in the enteric virome in inflammatory bowel disease. Cell 160(3):447–460PubMedPubMedCentralCrossRef
30.
Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel JF, Sands BE et al (2013) Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med 369(8):711–721PubMedCrossRef
31.
Langner C, Magro F, Driessen A, Ensari A, Mantzaris GJ, Villanacci V et al (2014) The histopathological approach to inflammatory bowel disease: a practice guide. Virchows Arch 464(5):511–527PubMed
32.
Magro F, Langner C, Driessen A, Ensari A, Geboes K, Mantzaris GJ et al (2013) European consensus on the histopathology of inflammatory bowel disease. J Crohns Colitis 7(10):827–851PubMedCrossRef
33.
Feakins RM, Gastroenterology BS (2013) Inflammatory bowel disease biopsies: updated British Society of Gastroenterology reporting guidelines. J Clin Pathol 66(12):1005–1026PubMedCrossRef
34.
Kleer CG, Appelman HD (1998) Ulcerative colitis: patterns of involvement in colorectal biopsies and changes with time. Am J Surg Pathol 22(8):983–989PubMedCrossRef
35.
Cross SS, Harrison RF (2002) Discriminant histological features in the diagnosis of chronic idiopathic inflammatory bowel disease: analysis of a large dataset by a novel data visualisation technique. J Clin Pathol 55(1):51–57PubMedPubMedCentralCrossRef
36.
Vavricka SR, Schoepfer A, Scharl M, Lakatos PL, Navarini A, Rogler G (2015) Extraintestinal manifestations of inflammatory bowel disease. Inflamm Bowel Dis 21(8):1982–1992PubMedPubMedCentralCrossRef
37.
Monsén U, Sorstad J, Hellers G, Johansson C (1990) Extracolonic diagnoses in ulcerative colitis: an epidemiological study. Am J Gastroenterol 85(6):711–716PubMed
38.
Das KM (1999) Relationship of extraintestinal involvements in inflammatory bowel disease: new insights into autoimmune pathogenesis. Dig Dis Sci 44(1):1–13PubMedCrossRef
39.
Ardizzone S, Puttini PS, Cassinotti A, Porro GB (2008) Extraintestinal manifestations of inflammatory bowel disease. Dig Liver Dis 40(Suppl 2):S253–S259PubMedCrossRef
40.
Veloso FT, Ferreira JT, Barros L, Almeida S (2001) Clinical outcome of Crohn’s disease: analysis according to the Vienna classification and clinical activity. Inflamm Bowel Dis 7(4):306–313PubMedCrossRef
41.
Greuter T, Bertoldo F, Rechner R, Straumann A, Biedermann L, Zeitz J et al (2016) Extraintestinal manifestations of pediatric inflammatory bowel disease: prevalence, presentation and anti-TNF treatment. J Pediatr Gastroenterol Nutr. doi:10.​1097/​MPG.​0000000000001455​
42.
Dotson JL, Hyams JS, Markowitz J, LeLeiko NS, Mack DR, Evans JS et al (2010) Extraintestinal manifestations of pediatric inflammatory bowel disease and their relation to disease type and severity. J Pediatr Gastroenterol Nutr 51(2):140–145PubMedCrossRef
43.
Jose FA, Garnett EA, Vittinghoff E, Ferry GD, Winter HS, Baldassano RN et al (2009) Development of extraintestinal manifestations in pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis 15(1):63–68PubMedCrossRef
44.
Guariso G, Gasparetto M, Visonà Dalla Pozza L, D'Incà R, Zancan L, Sturniolo G et al (2010) Inflammatory bowel disease developing in paediatric and adult age. J Pediatr Gastroenterol Nutr 51(6):698–707PubMedCrossRef
45.
Vind I, Riis L, Jess T, Knudsen E, Pedersen N, Elkjaer M et al (2006) Increasing incidences of inflammatory bowel disease and decreasing surgery rates in Copenhagen City and County, 2003–2005: a population-based study from the Danish Crohn colitis database. Am J Gastroenterol 101(6):1274–1282PubMedCrossRef
46.
Vavricka SR, Spigaglia SM, Rogler G, Pittet V, Michetti P, Felley C et al (2012) Systematic evaluation of risk factors for diagnostic delay in inflammatory bowel disease. Inflamm Bowel Dis 18(3):496–505PubMedCrossRef
47.
Schoepfer AM, Dehlavi MA, Fournier N, Safroneeva E, Straumann A, Pittet V et al (2013) Diagnostic delay in Crohn’s disease is associated with a complicated disease course and increased operation rate. Am J Gastroenterol 108(11):1744–1753
48.
Greenstein AJ, Janowitz HD, Sachar DB (1976) The extra-intestinal complications of Crohn’s disease and ulcerative colitis: a study of 700 patients. Medicine (Baltimore) 55(5):401–412CrossRef
49.
50.
Palamaras I, El-Jabbour J, Pietropaolo N, Thomson P, Mann S, Robles W et al (2008) Metastatic Crohn’s disease: a review. J Eur Acad Dermatol Venereol 22(9):1033–1043PubMedCrossRef
51.
Marzano AV, Borghi A, Stadnicki A, Crosti C, Cugno M (2014) Cutaneous manifestations in patients with inflammatory bowel diseases: pathophysiology, clinical features, and therapy. Inflamm Bowel Dis 20(1):213–227PubMedCrossRef
52.
Timani S, Mutasim DF (2008) Skin manifestations of inflammatory bowel disease. Clin Dermatol 26(3):265–273PubMedCrossRef
53.
Harbord M, Annese V, Vavricka SR, Allez M, Barreiro-de Acosta M, Boberg KM et al (2016) The first European evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease. J Crohns Colitis. 10(3):239–254PubMedCrossRef
54.
Vavricka SR, Rogler G, Gantenbein C, Spoerri M, Prinz Vavricka M, Navarini AA et al (2015) Chronological order of appearance of extraintestinal manifestations relative to the time of IBD diagnosis in the Swiss inflammatory bowel disease cohort. Inflamm Bowel Dis 21(8):1794–1800PubMedCrossRef
55.
Yüksel I, Başar O, Ataseven H, Ertuğrul I, Arhan M, Ibiş M et al (2009) Mucocutaneous manifestations in inflammatory bowel disease. Inflamm Bowel Dis 15(4):546–550PubMedCrossRef
56.
Huang W, McNeely MC (1997) Neutrophilic tissue reactions. Adv Dermatol 13:33–64PubMed
57.
Lakatos PL, Lakatos L, Kiss LS, Peyrin-Biroulet L, Schoepfer A, Vavricka S (2012) Treatment of extraintestinal manifestations in inflammatory bowel disease. Digestion 86(Suppl 1):28–35PubMedCrossRef
58.
Galbraith SS, Drolet BA, Kugathasan S, Paller AS, Esterly NB (2005) Asymptomatic inflammatory bowel disease presenting with mucocutaneous findings. Pediatrics 116(3):e439–e444PubMedCrossRef
59.
Levitt MD, Ritchie JK, Lennard-Jones JE, Phillips RK (1991) Pyoderma gangrenosum in inflammatory bowel disease. Br J Surg 78(6):676–678PubMedCrossRef
60.
Trikudanathan G, Venkatesh PG, Navaneethan U (2012) Diagnosis and therapeutic management of extra-intestinal manifestations of inflammatory bowel disease. Drugs 72(18):2333–2349PubMedCrossRef
61.
Polcz M, Gu J, Florin T (2011) Pyoderma gangrenosum in inflammatory bowel disease: the experience at Mater Health Services’ Adult Hospital 1998–2009. J Crohns Colitis 5(2):148–151PubMedCrossRef
62.
Menachem Y, Gotsman I (2004) Clinical manifestations of pyoderma gangrenosum associated with inflammatory bowel disease. Isr Med Assoc J 6(2):88–90PubMed
63.
Nguyen GC, Torres EA, Regueiro M, Bromfield G, Bitton A, Stempak J et al (2006) Inflammatory bowel disease characteristics among African Americans, Hispanics, and non-Hispanic Whites: characterization of a large North American cohort. Am J Gastroenterol 101(5):1012–1023PubMedCrossRef
64.
Freeman HJ (2005) Erythema nodosum and pyoderma gangrenosum in 50 patients with Crohn’s disease. Can J Gastroenterol 19(10):603–606PubMedCrossRef
65.
Xavier RJ, Podolsky DK (2007) Unravelling the pathogenesis of inflammatory bowel disease. Nature 448(7152):427–434PubMedCrossRef
66.
Lapidus A, Bernell O, Hellers G, Löfberg R (1998) Clinical course of colorectal Crohn’s disease: a 35-year follow-up study of 507 patients. Gastroenterology 114(6):1151–1160PubMedCrossRef
67.
Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN et al (2004) Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med 350(9):876–885PubMedCrossRef
68.
Lebwohl M, Fleischmajer R, Janowitz H, Present D, Prioleau PG (1984) Metastatic Crohn’s disease. J Am Acad Dermatol 10(1):33–38PubMedCrossRef
69.
Hawryluk EB, Izikson L, English JC (2010) Non-infectious granulomatous diseases of the skin and their associated systemic diseases: an evidence-based update to important clinical questions. Am J Clin Dermatol 11(3):171–181PubMedCrossRef
70.
Guest GD, Fink RL (2000) Metastatic Crohn’s disease: case report of an unusual variant and review of the literature. Dis Colon rectum 43(12):1764–1766
71.
Kafity AA, Pellegrini AE, Fromkes JJ (1993) Metastatic Crohn’s disease. A rare cutaneous manifestation. J Clin Gastroenterol 17(4):300–303PubMedCrossRef
72.
Hoffmann RM, Kruis W (2004) Rare extraintestinal manifestations of inflammatory bowel disease. Inflamm Bowel Dis 10(2):140–147PubMedCrossRef
73.
Konrad A, Seibold F (2003) Response of cutaneous Crohn’s disease to infliximab and methotrexate. Dig Liver Dis 35(5):351–356PubMedCrossRef
74.
Jorizzo JL, Solomon AR, Zanolli MD, Leshin B (1988) Neutrophilic vascular reactions. J Am Acad Dermatol 19(6):983–1005PubMedCrossRef
75.
Bennett ML, Jackson JM, Jorizzo JL, Fleischer AB, White WL, Callen JP (2000) Pyoderma gangrenosum. A comparison of typical and atypical forms with an emphasis on time to remission. Case review of 86 patients from 2 institutions. Medicine (Baltimore) 79(1):37–46CrossRef
76.
Farhi D, Cosnes J, Zizi N, Chosidow O, Seksik P, Beaugerie L et al (2008) Significance of erythema nodosum and pyoderma gangrenosum in inflammatory bowel diseases: a cohort study of 2402 patients. Medicine (Baltimore) 87(5):281–293CrossRef
77.
Rothfuss KS, Stange EF, Herrlinger KR (2006) Extraintestinal manifestations and complications in inflammatory bowel diseases. World J Gastroenterol 12(30):4819–4831PubMedPubMedCentralCrossRef
78.
79.
Weizman A, Huang B, Berel D, Targan SR, Dubinsky M, Fleshner P et al (2014) Clinical, serologic, and genetic factors associated with pyoderma gangrenosum and erythema nodosum in inflammatory bowel disease patients. Inflamm Bowel Dis 20(3):525–533PubMedPubMedCentralCrossRef
80.
Weenig RH, Davis MD, Dahl PR, Su WP (2002) Skin ulcers misdiagnosed as pyoderma gangrenosum. N Engl J Med 347(18):1412–1418PubMedCrossRef
81.
Powell RJ, Holbrook MR, Stevens A (1997) Pyoderma gangrenosum and its treatment. Lancet 350(9093):1720–1721PubMedCrossRef
82.
83.
Jolles S, Niclasse S, Benson E (1999) Combination oral and topical tacrolimus in therapy-resistant pyoderma gangrenosum. Br J Dermatol 140(3):564–565PubMedCrossRef
84.
Marzano AV, Trevisan V, Lazzari R, Crosti C (2011) Pyoderma gangrenosum: study of 21 patients and proposal of a ‘clinicotherapeutic’ classification. J Dermatolog Treat 22(5):254–260PubMedCrossRef
85.
Friedman S, Marion JF, Scherl E, Rubin PH, Present DH (2001) Intravenous cyclosporine in refractory pyoderma gangrenosum complicating inflammatory bowel disease. Inflamm Bowel Dis 7(1):1–7PubMedCrossRef
86.
Marzano AV, Ishak RS, Saibeni S, Crosti C, Meroni PL, Cugno M (2013) Autoinflammatory skin disorders in inflammatory bowel diseases, pyoderma gangrenosum and Sweet’s syndrome: a comprehensive review and disease classification criteria. Clin Rev Allergy Immunol 45(2):202–210PubMedCrossRef
87.
Brooklyn TN, Dunnill MG, Shetty A, Bowden JJ, Williams JD, Griffiths CE et al (2006) Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut 55(4):505–509PubMedPubMedCentralCrossRef
88.
Argüelles-Arias F, Castro-Laria L, Lobatón T, Aguas-Peris M, Rojas-Feria M, Barreiro-de Acosta M et al (2013) Characteristics and treatment of pyoderma gangrenosum in inflammatory bowel disease. Dig Dis Sci 58(10):2949–2954PubMedCrossRef
89.
Vavricka SR, Gubler M, Gantenbein C, Spoerri M, Fröhlich F, Seibold F et al (2017) Anti-TNF treatment for extraintestinal manifestations of inflammatory bowel disease in the Swiss IBD Cohort Study. Inflamm Bowel Dis 23(7):1174–1181
90.
Schoch JJ, Tolkachjov SN, Cappel JA, Gibson LE, Davis DM (2017) Pediatric pyoderma gangrenosum: a retrospective review of clinical features, etiologic associations, and treatment. Pediatr Dermatol 34(1):39–45PubMedCrossRef
91.
Becuwe C, Delaporte E, Colombel JF, Piette F, Cortot A, Bergoend H (1989) Sweet’s syndrome associated with Crohn’s disease. Acta Derm Venereol 69(5):444–445PubMed
92.
Cohen PR, Kurzrock R (2003) Sweet’s syndrome revisited: a review of disease concepts. Int J Dermatol 42(10):761–778PubMedCrossRef
93.
94.
95.
Travis S, Innes N, Davies MG, Daneshmend T, Hughes S (1997) Sweet’s syndrome: an unusual cutaneous feature of Crohn’s disease or ulcerative colitis. The South West Gastroenterology Group. Eur J Gastroenterol Hepatol 9(7):715–720PubMedCrossRef
96.
Catalán-Serra I, Martín-Moraleda L, Navarro-López L, Gil-Borrás R, Pont-Sanjuán V, Ferrando-Marco J et al (2010) Crohn’s disease and Sweet’s syndrome: an uncommon association. Rev Esp Enferm Dig 102(5):331–337PubMedCrossRef
97.
von den Driesch P (1994) Sweet’s syndrome (acute febrile neutrophilic dermatosis). J Am Acad Dermatol 31(4):535–556
98.
Mert A, Ozaras R, Tabak F, Pekmezci S, Demirkesen C, Ozturk R (2004) Erythema nodosum: an experience of 10 years. Scand J Infect Dis 36(6–7):424–427PubMedCrossRef
99.
Apgar JT (1991) Newer aspects of inflammatory bowel disease and its cutaneous manifestations: a selective review. Semin Dermatol 10(3):138–147PubMed
100.
101.
Löfberg R, Louis EV, Reinisch W, Robinson AM, Kron M, Camez A et al (2012) Adalimumab produces clinical remission and reduces extraintestinal manifestations in Crohn’s disease: results from CARE. Inflamm Bowel Dis 18(1):1–9PubMedCrossRef
102.
Clayton TH, Walker BP, Stables GI (2006) Treatment of chronic erythema nodosum with infliximab. Clin Exp Dermatol 31(6):823–824PubMedCrossRef
103.
Quin A, Kane S, Ulitsky O (2008) A case of fistulizing Crohn’s disease and erythema nodosum managed with adalimumab. Nat Clin Pract Gastroenterol Hepatol 5(5):278–281PubMedCrossRef
104.
Kugathasan S, Miranda A, Nocton J, Drolet BA, Raasch C, Binion DG (2003) Dermatologic manifestations of Crohn disease in children: response to infliximab. J Pediatr Gastroenterol Nutr 37(2):150–154PubMedCrossRef
105.
Ortego-Centeno N, Callejas-Rubio JL, Sanchez-Cano D, Caballero-Morales T (2007) Refractory chronic erythema nodosum successfully treated with adalimumab. J Eur Acad Dermatol Venereol 21(3):408–410PubMedCrossRef
106.
Vavricka SR, Manser CN, Hediger S, Vögelin M, Scharl M, Biedermann L et al (2013) Periodontitis and gingivitis in inflammatory bowel disease: a case-control study. Inflamm Bowel Dis 19(13):2768–2777PubMedCrossRef
107.
VanHale HM, Rogers RS, Doyle JA, Schroeter AL (1981) Immunofluorescence microscopic studies of recurrent aphthous stomatitis. Arch Dermatol 117(12):779–781PubMedCrossRef
108.
109.
Habashneh RA, Khader YS, Alhumouz MK, Jadallah K, Ajlouni Y (2012) The association between inflammatory bowel disease and periodontitis among Jordanians: a case-control study. J Periodontal Res 47(3):293–298PubMedCrossRef
110.
Kaufman I, Caspi D, Yeshurun D, Dotan I, Yaron M, Elkayam O (2005) The effect of infliximab on extraintestinal manifestations of Crohn’s disease. Rheumatol Int 25(6):406–410PubMedCrossRef
111.
Fiorino G, Allez M, Malesci A, Danese S (2009) Review article: anti TNF-alpha induced psoriasis in patients with inflammatory bowel disease. Aliment Pharmacol Ther 29(9):921–927PubMedCrossRef
112.
Fiorino G, Danese S, Pariente B, Allez M (2014) Paradoxical immune-mediated inflammation in inflammatory bowel disease patients receiving anti-TNF-α agents. Autoimmun Rev 13(1):15–19PubMedCrossRef
113.
Cullen G, Kroshinsky D, Cheifetz AS, Korzenik JR (2011) Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature. Aliment Pharmacol Ther 34(11–12):1318–1327PubMedCrossRef
114.
Rahier JF, Buche S, Peyrin-Biroulet L, Bouhnik Y, Duclos B, Louis E et al (2010) Severe skin lesions cause patients with inflammatory bowel disease to discontinue anti-tumor necrosis factor therapy. Clin Gastroenterol Hepatol 8(12):1048–1055PubMedCrossRef
115.
Ramos-Casals M, Brito-Zerón P, Muñoz S, Soria N, Galiana D, Bertolaccini L et al (2007) Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore) 86(4):242–251CrossRef
116.
Palucka AK, Blanck JP, Bennett L, Pascual V, Banchereau J (2005) Cross-regulation of TNF and IFN-alpha in autoimmune diseases. Proc Natl Acad Sci U S A 102(9):3372–3377PubMedPubMedCentralCrossRef
117.
de Gannes GC, Ghoreishi M, Pope J, Russell A, Bell D, Adams S et al (2007) Psoriasis and pustular dermatitis triggered by TNF-{alpha} inhibitors in patients with rheumatologic conditions. Arch Dermatol 143(2):223–231PubMedCrossRef
118.
Nestle FO, Gilliet M (2005) Defining upstream elements of psoriasis pathogenesis: an emerging role for interferon alpha. J Invest Dermatol 125(5):xiv–xxvPubMedCrossRef
119.
Notley CA, Inglis JJ, Alzabin S, McCann FE, McNamee KE, Williams RO (2008) Blockade of tumor necrosis factor in collagen-induced arthritis reveals a novel immunoregulatory pathway for Th1 and Th17 cells. J Exp Med 205(11):2491–2497PubMedPubMedCentralCrossRef
120.
Tillack C, Ehmann LM, Friedrich M, Laubender RP, Papay P, Vogelsang H et al (2014) Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-γ-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment. Gut 63(4):567–577PubMedCrossRef
121.
Andrisani G, Marzo M, Celleno L, Guidi L, Papa A, Gasbarrini A et al (2013) Development of psoriasis scalp with alopecia during treatment of Crohn’s disease with infliximab and rapid response to both diseases to ustekinumab. Eur Rev Med Pharmacol Sci 17(20):2831–2836PubMed
122.
Gregoriou S, Kazakos C, Christofidou E, Kontochristopoulos G, Vakis G, Rigopoulos D (2011) Pustular psoriasis development after initial ustekinumab administration in chronic plaque psoriasis. Eur J Dermatol 21(1):104–105PubMed
123.
Peyrin-Biroulet L, Van Assche G, Gómez-Ulloa D, García-Álvarez L, Lara N, Black CM, et al. Systematic review of tumor necrosis factor antagonists in extraintestinal manifestations in inflammatory bowel disease. Clin Gastroenterol Hepatol. 2016.
124.
Barreiro-de-Acosta M, Lorenzo A, Domínguez-Muñoz JE (2012) Efficacy of adalimumab for the treatment of extraintestinal manifestations of Crohn’s disease. Rev Esp Enferm Dig 104(9):468–472PubMedCrossRef
125.
Rispo A, Scarpa R, Di Girolamo E, Cozzolino A, Lembo G, Atteno M et al (2005) Infliximab in the treatment of extra-intestinal manifestations of Crohn’s disease. Scand J Rheumatol 34(5):387–391PubMedCrossRef
126.
Caspersen S, Elkjaer M, Riis L, Pedersen N, Mortensen C, Jess T et al (2008) Infliximab for inflammatory bowel disease in Denmark 1999–2005: clinical outcome and follow-up evaluation of malignancy and mortality. Clin Gastroenterol Hepatol 6(11):1212–1217
Metadata
Title
Skin Manifestations of Inflammatory Bowel Disease
Authors
Thomas Greuter
Alexander Navarini
Stephan R. Vavricka
Publication date
01-12-2017
Publisher
Springer US
Published in
Clinical Reviews in Allergy & Immunology / Issue 3/2017
Print ISSN: 1080-0549
Electronic ISSN: 1559-0267
DOI
https://doi.org/10.1007/s12016-017-8617-4

Other articles of this Issue 3/2017

Clinical Reviews in Allergy & Immunology 3/2017 Go to the issue

ReviewPaper

Neonatal Systemic Lupus Erythematosus Syndrome: a Comprehensive Review

ReviewPaper

Cutaneous Manifestations of ANCA-Associated Small Vessels Vasculitis

ReviewPaper

Cutaneous Manifestations of Scleroderma and Scleroderma-Like Disorders: a Comprehensive Review

ReviewPaper

Cutaneous Manifestations of Medium- and Large-Vessel Vasculitis

ReviewPaper

Cutaneous and Mucosal Manifestations of Sjögren’s Syndrome

ReviewPaper

Skin Manifestations Associated with Autoimmune Liver Diseases: a Systematic Review
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits